- PIPELINE
- COMPANY
- NEWS & PUBLICATIONS
- Company news
- Micar 21 Ltd started to provide to customers discovery of novel active substances for medicinal cosmetics development.
- New! A pioneering study focused on the prevention of hypertrophic cardiomyopathy (HCM) among individuals with a sarcomere gene mutation (Feb. 2015)
- Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
- Structural and Dynamical Insight into PPARγ
- Try our outsourcing services!
- Identification of P-glycoprotein binders based on in house prepared diverse set of structures
- PPARγ helix 12 exhibits an antagonist conformation
- PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
- Micar Innovation (Micar21) TOP 8 BioTech Award by Delta Ventures and the TOP 50 of the 2018 Startup World Cup & Summit Regional Finals!
- Diplomatic World
- Micar Innovation listed as a Emerging Players
- Micar Innovation is One of 250 Companies
- Micar Innovation (Micar21) is the winner of а prestigious award for Innovative enterprise of the year 2018
- AI for Drug Discovery Biomarker Development
- Discovery of the first class of dual CCR5/7 antagonists for COVID-19
- Covid B.1.1.529
- Scientific publications
- Combination of Genetic Screening and Molecular Dynamics as a Useful Tool for Identification of Disease-Related Mutations: ZASP PDZ Domain G54S Mutation Case
- Structural insight into the UNC-45–myosin complex
- Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow
- Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study
- Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
- Structural and Dynamical Insight into PPARγ Antagonism: In silico Study of the Ligand-Receptor Interactions of non-Covalent Antagonists
- Molecular dynamics simulation of the human estrogen receptor alpha: contribution to the pharmacophore of the agonists
- PPARγ helix 12 exhibits an antagonist conformation
- PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
- Prediction of Accurate Binding Modes using Combination of classical and accelerated Molecular dynamics and Free Energy Perturbation Calculations: An Application to Toxicity Studies
- An Improvement of the Free Energy Perturbation (FEP+) Sampling Protocol in Case of Flexible protein Ligand Binding Sites
- Combination of Structural based Pharmacophore and Docking Virtual Screens: An Efficient Structure-based Protocol for Lead Identification
- Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies
- Discovery of New Classes of Glycine transporter 2 (GlyT2) Inhibitors and GlyT2 Selectivity Studies
- Discovery of New AKT1 Inhibitors by Combination of In silico Structure Based Virtual Screening Approaches and Biological Evaluations
- N501Y_mutation_manuscript
- N501Y and K417N mutation manuscript
- Achievements & Awards
- Interview in the news
- Analytics reports
- Events
- Company news
MIGUEL RIVERA CELLULAR AND MOLECULAR BIOCHEMISTRY
Miguel Rivera is a talented researcher who has recently joint to our team and are responsible for our USA based activities connected to Micar Innovation Drug Discovery Services. He came from University of Texas at El Paso.
- erivera@micar21.com
- hUSA
- wwww.micar21.com
Micar21 (Micar Innovation) © 2016 - 2024 All rights reserved.